سعر ميتادرونيك 4مجم/5مل فيال 2024

Zoledronic acid 4 mg/5 ml concentrate in a single vial for dilution and intravenous infusion; bisphosphonate.

• Hypercalcaemia of malignancy.Population: AdultsDailyMed (U.S. National Library of Medicine)
• Multiple myeloma and bone metastases of solid tumours, in conjunction with standard antineoplastic therapy.Population: AdultsDailyMed (U.S. National Library of Medicine)

• Acute-phase reaction within 3 days of infusion (fever, fatigue, bone pain, arthralgia, myalgia, influenza-like illness); also renal function deterioration, hypocalcaemia and other electrolyte disturbances, and osteonecrosis of the jaw.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Hypersensitivity to zoledronic acid or any component; hypersensitivity reactions including rare urticaria, angioedema and anaphylaxis have been reported.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Patients must be adequately hydrated before administration; monitor serum calcium, phosphate, magnesium and creatinine.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Renal toxicity: single doses above 4 mg or infusions shorter than 15 minutes increase the risk of renal deterioration, which may progress to renal failure.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Osteonecrosis of the jaw: perform a dental examination with appropriate preventive dentistry before treatment and avoid invasive dental procedures during treatment where possible.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Aminoglycosides and calcitoninMay have an additive calcium-lowering effect over a prolonged period; monitor serum calcium.DailyMed (U.S. National Library of Medicine)
• Loop diureticsIncreased risk of hypocalcaemia.DailyMed (U.S. National Library of Medicine)
• Nephrotoxic drugsUse with caution because of potential additive renal toxicity.DailyMed (U.S. National Library of Medicine)

• Can cause fetal harm based on animal data and mechanism of action; bisphosphonates are retained in bone and released over years. Females of reproductive potential should use effective contraception.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Advise women not to breastfeed during treatment (potential serious adverse reactions in the breastfed infant).International label, same formulation · DailyMed (U.S. National Library of Medicine)

English text not available for this section.